Pharmaceutical Companies
- 562.098
- +3.199+0.57%
One picture to understand | The list of bull and bear stocks in Hong Kong stocks for November is out! AI application stocks have surged, mobvista has risen by 300% this month.
Entering the Middle Eastern market! dalipal hldg has seen a monthly increase of over 80%, and will partner with Saudi Aramco to build a production base in the Middle East.
The new version of the medical insurance list adds 11 Chinese patent medicine varieties. Traditional Chinese medicine innovative drugs, classic famous prescriptions, and children's medications receive key support.
In 2024, the national medical insurance catalog was officially released today, with 91 pharmaceuticals newly added to the national medical insurance drug catalog, with an average price reduction of 63%; this time there are 11 new chinese patent medicines added, 10 of which are new drugs approved for marketing last year and this year.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Middle East, North Africa! China's biotech is heading to new destinations.
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
Third quarter IPO report: Hong Kong stock market once again witnessed billion-dollar projects, the number and amount of Chinese enterprise IPOs rebounded year-on-year
In Q3 2024, a total of 52 Chinese companies successfully IPO'd on A-shares, Hong Kong stocks, and US stocks. The number of IPOs decreased by 52.29% year-on-year, but increased by 18.18% compared to the previous period. In the first three quarters, the number of IPOs of Chinese companies globally decreased by 54.98% year-on-year.
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A few days ago, a leaked document of the tenth batch of national procurement reporting list circulated within the industry. Today, when reporters verified with the relevant department, they indicated that it is an internal document not for public disclosure, and the formal centralized procurement document will be released publicly in the future; ② Several industry experts have informed reporters that this reporting list does not represent the final procurement list, but the competitive landscape of the tenth batch of national procurement will start with at least seven companies; ③ The competition for the tenth batch of national procurement will be particularly intense.
Weekend reading | merck's 'harem battle'
为了让K药价值持续放大，默沙东开启了一场全球ADC寻觅之旅。
Who's buying? The A-share market is closed, but the Hong Kong stock market is still going strong! There's a big shift in foreign capital underway.
According to the latest report published by Goldman Sachs, after the People's Bank of China announced easing measures and the September Political Bureau meeting, mainland consumer stocks rebounded strongly by an average of about 32% in the past week.
CANbridge Pharmaceuticals' CAN103 for Gaucher Disease has been granted Priority Review Status by the Center for Drug Evaluation of the National Medical Products Administration.
The central bank has launched two measures at the same time! The reserve requirement ratio is reduced by 0.5 percentage points, and the 7-day reverse repurchase operation interest rate is lowered by 20 basis points.
Starting from September 27, 2024, the reserve requirement ratio for financial institutions is reduced by 0.5 percentage points. After this reduction, the weighted average reserve requirement ratio for financial institutions is approximately 6.6%.
From January to July, the cumulative scale of the national retail pharmacy market reached 299.1 billion yuan, a year-on-year decrease of 3.3%.
The listing of Dapagliflozin Metformin ER tablets will further intensify the competition in the domestic antidiabetic drug market.
Announcement Selection | cspc pharma plans to repurchase up to 5 billion Hong Kong dollars of shares; Sun Insurance: Sunshine Life Insurance premium income from January to August is 66.384 billion yuan
China Railway Signal & Communication Corporation (03969.HK) won a total of approximately 2.9 billion yuan worth of projects from July to August; Tencent (00700.HK) spent 1.002 billion Hong Kong dollars on repurchasing 2.6 million shares on September 19; Alibaba-SW (09988.HK) spent 59.977 million US dollars on repurchasing 5.678 million shares on September 18.
The first domestically produced IL-4Rα monoclonal antibody has been approved for marketing, targeting competitors with annual sales exceeding 10 billion US dollars.
①Dupilumab has been approved for the treatment of moderate to severe atopic dermatitis in adults, not only becoming the first domestically approved IL-4Rα antibody drug, but also the second IL-4Rα antibody drug approved globally; ②In addition to Regdanvimab, as of the first half of 2024, there are at least 10 domestic companies researching IL-4Rα monoclonal antibody drugs.